Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haloperidol + lidocaine is a non-standard, unbranded combination of two established drugs—haloperidol, a first-generation (typical) antipsychotic, and lidocaine, an amide-type local anesthetic. Haloperidol acts primarily as a dopamine D2 receptor antagonist in the central nervous system and is used to treat schizophrenia, acute psychosis, agitation, Tourette syndrome tics, and other severe behavioral disorders[1][9]. Lidocaine blocks voltage-gated sodium channels in neuronal membranes to inhibit nerve impulse conduction and is widely used for local or regional anesthesia by infiltration or nerve block techniques[3]. There are no widely recognized fixed-dose combination products of these two agents; if co-administered (for example during procedures requiring both sedation/antipsychotic effect and local anesthesia), their effects are additive on the central nervous system. Coadministration may increase risks such as CNS depression (drowsiness, confusion), impaired judgment or psychomotor skills[2][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on haloperidol + lidocaine.